Economic Evaluation Associated With Clinical-Grade Mobile App-Based Digital Therapeutic Interventions: Systematic Review
Digital therapeutics (DTx), a class of software-based clinical interventions, are promising new technologies that can potentially prevent, manage, or treat a spectrum of medical disorders and diseases as well as deliver unprecedented portability for patients and scalability for health care providers...
Gespeichert in:
Veröffentlicht in: | Journal of medical Internet research 2023-08, Vol.25 (1), p.e47094-e47094 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | e47094 |
---|---|
container_issue | 1 |
container_start_page | e47094 |
container_title | Journal of medical Internet research |
container_volume | 25 |
creator | Sapanel, Yoann Tadeo, Xavier Brenna, Connor T A Remus, Alexandria Koerber, Florian Cloutier, L Martin Tremblay, Gabriel Blasiak, Agata Hardesty, Chris L Yoong, Joanne Ho, Dean |
description | Digital therapeutics (DTx), a class of software-based clinical interventions, are promising new technologies that can potentially prevent, manage, or treat a spectrum of medical disorders and diseases as well as deliver unprecedented portability for patients and scalability for health care providers. Their adoption and implementation were accelerated by the need for remote care during the COVID-19 pandemic, and awareness about their utility has rapidly grown among providers, payers, and regulators. Despite this, relatively little is known about the capacity of DTx to provide economic value in care.
This study aimed to systematically review and summarize the published evidence regarding the cost-effectiveness of clinical-grade mobile app-based DTx and explore the factors affecting such evaluations.
A systematic review of economic evaluations of clinical-grade mobile app-based DTx was conducted following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 2020 guidelines. Major electronic databases, including PubMed, Cochrane Library, and Web of Science, were searched for eligible studies published from inception to October 28, 2022. Two independent reviewers evaluated the eligibility of all the retrieved articles for inclusion in the review. Methodological quality and risk of bias were assessed for each included study.
A total of 18 studies were included in this review. Of the 18 studies, 7 (39%) were nonrandomized study-based economic evaluations, 6 (33%) were model-based evaluations, and 5 (28%) were randomized clinical trial-based evaluations. The DTx intervention subject to assessment was found to be cost-effective in 12 (67%) studies, cost saving in 5 (28%) studies, and cost-effective in 1 (6%) study in only 1 of the 3 countries where it was being deployed in the final study. Qualitative deficiencies in methodology and substantial potential for bias, including risks of performance bias and selection bias in participant recruitment, were identified in several included studies.
This systematic review supports the thesis that DTx interventions offer potential economic benefits. However, DTx economic analyses conducted to date exhibit important methodological shortcomings that must be addressed in future evaluations to reduce the uncertainty surrounding the widespread adoption of DTx interventions.
PROSPERO International Prospective Register of Systematic Reviews CRD42022358616; https://www.crd.york.ac.uk/prospero/display_record |
doi_str_mv | 10.2196/47094 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10427932</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2844677956</sourcerecordid><originalsourceid>FETCH-LOGICAL-c392t-ca0e6f389ed67c5656d34498c355ba2d8f38ab3a51bed472e5adedb643e36b383</originalsourceid><addsrcrecordid>eNpdkV1rFDEYhYMottb-BRkQoTej-Zpk4o2s61oLFUErXoZM5t1uSmYyJplt---btR-0XuWF8_BwwkHokOD3lCjxgUus-DO0Tzhr67aV5Pmjew-9SukCY4q5Ii_RHpMNFUqyfXS1smEMg7PVamv8bLILY7VIKVhnMvTVH5c31dK70Vnj6-Noeqi-h855qBbTVH82qUBf3LnLxldnG4hmgjkX3cmYIW5h3AnTx-rXdcowmF3yE7YOLl-jF2vjExzevQfo99fV2fJbffrj-GS5OK0tUzTX1mAQa9Yq6IW0jWhEzzhXrWVN0xnatyUzHTMN6aDnkkJTGvad4AyY6FjLDtCnW-80dwP0tjSKxuspusHEax2M00-T0W30edhqgjmVitFiOLozxPB3hpT14JIF780IYU6atpwLKVUjCvr2P_QizHEs_9NUESmoEgwX6t0tZWNIKcL6oQ3Bejem_jdm4d48rv5A3a_HbgC5xZsj</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2917629630</pqid></control><display><type>article</type><title>Economic Evaluation Associated With Clinical-Grade Mobile App-Based Digital Therapeutic Interventions: Systematic Review</title><source>Applied Social Sciences Index & Abstracts (ASSIA)</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central</source><source>EZB Electronic Journals Library</source><source>PubMed Central Open Access</source><creator>Sapanel, Yoann ; Tadeo, Xavier ; Brenna, Connor T A ; Remus, Alexandria ; Koerber, Florian ; Cloutier, L Martin ; Tremblay, Gabriel ; Blasiak, Agata ; Hardesty, Chris L ; Yoong, Joanne ; Ho, Dean</creator><creatorcontrib>Sapanel, Yoann ; Tadeo, Xavier ; Brenna, Connor T A ; Remus, Alexandria ; Koerber, Florian ; Cloutier, L Martin ; Tremblay, Gabriel ; Blasiak, Agata ; Hardesty, Chris L ; Yoong, Joanne ; Ho, Dean</creatorcontrib><description>Digital therapeutics (DTx), a class of software-based clinical interventions, are promising new technologies that can potentially prevent, manage, or treat a spectrum of medical disorders and diseases as well as deliver unprecedented portability for patients and scalability for health care providers. Their adoption and implementation were accelerated by the need for remote care during the COVID-19 pandemic, and awareness about their utility has rapidly grown among providers, payers, and regulators. Despite this, relatively little is known about the capacity of DTx to provide economic value in care.
This study aimed to systematically review and summarize the published evidence regarding the cost-effectiveness of clinical-grade mobile app-based DTx and explore the factors affecting such evaluations.
A systematic review of economic evaluations of clinical-grade mobile app-based DTx was conducted following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 2020 guidelines. Major electronic databases, including PubMed, Cochrane Library, and Web of Science, were searched for eligible studies published from inception to October 28, 2022. Two independent reviewers evaluated the eligibility of all the retrieved articles for inclusion in the review. Methodological quality and risk of bias were assessed for each included study.
A total of 18 studies were included in this review. Of the 18 studies, 7 (39%) were nonrandomized study-based economic evaluations, 6 (33%) were model-based evaluations, and 5 (28%) were randomized clinical trial-based evaluations. The DTx intervention subject to assessment was found to be cost-effective in 12 (67%) studies, cost saving in 5 (28%) studies, and cost-effective in 1 (6%) study in only 1 of the 3 countries where it was being deployed in the final study. Qualitative deficiencies in methodology and substantial potential for bias, including risks of performance bias and selection bias in participant recruitment, were identified in several included studies.
This systematic review supports the thesis that DTx interventions offer potential economic benefits. However, DTx economic analyses conducted to date exhibit important methodological shortcomings that must be addressed in future evaluations to reduce the uncertainty surrounding the widespread adoption of DTx interventions.
PROSPERO International Prospective Register of Systematic Reviews CRD42022358616; https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022358616.</description><identifier>ISSN: 1438-8871</identifier><identifier>ISSN: 1439-4456</identifier><identifier>EISSN: 1438-8871</identifier><identifier>DOI: 10.2196/47094</identifier><identifier>PMID: 37526973</identifier><language>eng</language><publisher>Canada: Gunther Eysenbach MD MPH, Associate Professor</publisher><subject>Bias ; Clinical assessment ; Clinical outcomes ; Clinical research ; Clinical trials ; Clinical Trials as Topic ; Cost analysis ; Cost control ; Cost-Benefit Analysis ; COVID-19 ; Digital technology ; Economic impact ; FDA approval ; Health care ; Health technology assessment ; Humans ; Intervention ; Medical equipment ; Medical personnel ; Mobile Applications ; Pandemics ; Patients ; Recruitment ; Reimbursement ; Research methodology ; Review ; Risk assessment ; Selection bias ; Sensitivity analysis ; Software ; Systematic review ; Telemedicine ; Uncertainty ; Value ; Virtual reality</subject><ispartof>Journal of medical Internet research, 2023-08, Vol.25 (1), p.e47094-e47094</ispartof><rights>Yoann Sapanel, Xavier Tadeo, Connor T A Brenna, Alexandria Remus, Florian Koerber, L Martin Cloutier, Gabriel Tremblay, Agata Blasiak, Chris L Hardesty, Joanne Yoong, Dean Ho. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 01.08.2023.</rights><rights>2023. This work is licensed under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Yoann Sapanel, Xavier Tadeo, Connor T A Brenna, Alexandria Remus, Florian Koerber, L Martin Cloutier, Gabriel Tremblay, Agata Blasiak, Chris L Hardesty, Joanne Yoong, Dean Ho. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 01.08.2023. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c392t-ca0e6f389ed67c5656d34498c355ba2d8f38ab3a51bed472e5adedb643e36b383</citedby><cites>FETCH-LOGICAL-c392t-ca0e6f389ed67c5656d34498c355ba2d8f38ab3a51bed472e5adedb643e36b383</cites><orcidid>0009-0009-3578-9594 ; 0000-0003-0727-7611 ; 0000-0002-0162-9885 ; 0000-0001-6797-7850 ; 0000-0002-6126-3897 ; 0000-0001-9001-3128 ; 0000-0001-5410-791X ; 0000-0001-9002-7933 ; 0009-0007-0922-558X ; 0000-0002-7337-296X ; 0000-0003-0356-826X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,723,776,780,860,881,12827,27903,27904,30978</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37526973$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sapanel, Yoann</creatorcontrib><creatorcontrib>Tadeo, Xavier</creatorcontrib><creatorcontrib>Brenna, Connor T A</creatorcontrib><creatorcontrib>Remus, Alexandria</creatorcontrib><creatorcontrib>Koerber, Florian</creatorcontrib><creatorcontrib>Cloutier, L Martin</creatorcontrib><creatorcontrib>Tremblay, Gabriel</creatorcontrib><creatorcontrib>Blasiak, Agata</creatorcontrib><creatorcontrib>Hardesty, Chris L</creatorcontrib><creatorcontrib>Yoong, Joanne</creatorcontrib><creatorcontrib>Ho, Dean</creatorcontrib><title>Economic Evaluation Associated With Clinical-Grade Mobile App-Based Digital Therapeutic Interventions: Systematic Review</title><title>Journal of medical Internet research</title><addtitle>J Med Internet Res</addtitle><description>Digital therapeutics (DTx), a class of software-based clinical interventions, are promising new technologies that can potentially prevent, manage, or treat a spectrum of medical disorders and diseases as well as deliver unprecedented portability for patients and scalability for health care providers. Their adoption and implementation were accelerated by the need for remote care during the COVID-19 pandemic, and awareness about their utility has rapidly grown among providers, payers, and regulators. Despite this, relatively little is known about the capacity of DTx to provide economic value in care.
This study aimed to systematically review and summarize the published evidence regarding the cost-effectiveness of clinical-grade mobile app-based DTx and explore the factors affecting such evaluations.
A systematic review of economic evaluations of clinical-grade mobile app-based DTx was conducted following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 2020 guidelines. Major electronic databases, including PubMed, Cochrane Library, and Web of Science, were searched for eligible studies published from inception to October 28, 2022. Two independent reviewers evaluated the eligibility of all the retrieved articles for inclusion in the review. Methodological quality and risk of bias were assessed for each included study.
A total of 18 studies were included in this review. Of the 18 studies, 7 (39%) were nonrandomized study-based economic evaluations, 6 (33%) were model-based evaluations, and 5 (28%) were randomized clinical trial-based evaluations. The DTx intervention subject to assessment was found to be cost-effective in 12 (67%) studies, cost saving in 5 (28%) studies, and cost-effective in 1 (6%) study in only 1 of the 3 countries where it was being deployed in the final study. Qualitative deficiencies in methodology and substantial potential for bias, including risks of performance bias and selection bias in participant recruitment, were identified in several included studies.
This systematic review supports the thesis that DTx interventions offer potential economic benefits. However, DTx economic analyses conducted to date exhibit important methodological shortcomings that must be addressed in future evaluations to reduce the uncertainty surrounding the widespread adoption of DTx interventions.
PROSPERO International Prospective Register of Systematic Reviews CRD42022358616; https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022358616.</description><subject>Bias</subject><subject>Clinical assessment</subject><subject>Clinical outcomes</subject><subject>Clinical research</subject><subject>Clinical trials</subject><subject>Clinical Trials as Topic</subject><subject>Cost analysis</subject><subject>Cost control</subject><subject>Cost-Benefit Analysis</subject><subject>COVID-19</subject><subject>Digital technology</subject><subject>Economic impact</subject><subject>FDA approval</subject><subject>Health care</subject><subject>Health technology assessment</subject><subject>Humans</subject><subject>Intervention</subject><subject>Medical equipment</subject><subject>Medical personnel</subject><subject>Mobile Applications</subject><subject>Pandemics</subject><subject>Patients</subject><subject>Recruitment</subject><subject>Reimbursement</subject><subject>Research methodology</subject><subject>Review</subject><subject>Risk assessment</subject><subject>Selection bias</subject><subject>Sensitivity analysis</subject><subject>Software</subject><subject>Systematic review</subject><subject>Telemedicine</subject><subject>Uncertainty</subject><subject>Value</subject><subject>Virtual reality</subject><issn>1438-8871</issn><issn>1439-4456</issn><issn>1438-8871</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>7QJ</sourceid><sourceid>BENPR</sourceid><recordid>eNpdkV1rFDEYhYMottb-BRkQoTej-Zpk4o2s61oLFUErXoZM5t1uSmYyJplt---btR-0XuWF8_BwwkHokOD3lCjxgUus-DO0Tzhr67aV5Pmjew-9SukCY4q5Ii_RHpMNFUqyfXS1smEMg7PVamv8bLILY7VIKVhnMvTVH5c31dK70Vnj6-Noeqi-h855qBbTVH82qUBf3LnLxldnG4hmgjkX3cmYIW5h3AnTx-rXdcowmF3yE7YOLl-jF2vjExzevQfo99fV2fJbffrj-GS5OK0tUzTX1mAQa9Yq6IW0jWhEzzhXrWVN0xnatyUzHTMN6aDnkkJTGvad4AyY6FjLDtCnW-80dwP0tjSKxuspusHEax2M00-T0W30edhqgjmVitFiOLozxPB3hpT14JIF780IYU6atpwLKVUjCvr2P_QizHEs_9NUESmoEgwX6t0tZWNIKcL6oQ3Bejem_jdm4d48rv5A3a_HbgC5xZsj</recordid><startdate>20230801</startdate><enddate>20230801</enddate><creator>Sapanel, Yoann</creator><creator>Tadeo, Xavier</creator><creator>Brenna, Connor T A</creator><creator>Remus, Alexandria</creator><creator>Koerber, Florian</creator><creator>Cloutier, L Martin</creator><creator>Tremblay, Gabriel</creator><creator>Blasiak, Agata</creator><creator>Hardesty, Chris L</creator><creator>Yoong, Joanne</creator><creator>Ho, Dean</creator><general>Gunther Eysenbach MD MPH, Associate Professor</general><general>JMIR Publications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QJ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>CNYFK</scope><scope>DWQXO</scope><scope>E3H</scope><scope>F2A</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1O</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0009-0009-3578-9594</orcidid><orcidid>https://orcid.org/0000-0003-0727-7611</orcidid><orcidid>https://orcid.org/0000-0002-0162-9885</orcidid><orcidid>https://orcid.org/0000-0001-6797-7850</orcidid><orcidid>https://orcid.org/0000-0002-6126-3897</orcidid><orcidid>https://orcid.org/0000-0001-9001-3128</orcidid><orcidid>https://orcid.org/0000-0001-5410-791X</orcidid><orcidid>https://orcid.org/0000-0001-9002-7933</orcidid><orcidid>https://orcid.org/0009-0007-0922-558X</orcidid><orcidid>https://orcid.org/0000-0002-7337-296X</orcidid><orcidid>https://orcid.org/0000-0003-0356-826X</orcidid></search><sort><creationdate>20230801</creationdate><title>Economic Evaluation Associated With Clinical-Grade Mobile App-Based Digital Therapeutic Interventions: Systematic Review</title><author>Sapanel, Yoann ; Tadeo, Xavier ; Brenna, Connor T A ; Remus, Alexandria ; Koerber, Florian ; Cloutier, L Martin ; Tremblay, Gabriel ; Blasiak, Agata ; Hardesty, Chris L ; Yoong, Joanne ; Ho, Dean</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c392t-ca0e6f389ed67c5656d34498c355ba2d8f38ab3a51bed472e5adedb643e36b383</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Bias</topic><topic>Clinical assessment</topic><topic>Clinical outcomes</topic><topic>Clinical research</topic><topic>Clinical trials</topic><topic>Clinical Trials as Topic</topic><topic>Cost analysis</topic><topic>Cost control</topic><topic>Cost-Benefit Analysis</topic><topic>COVID-19</topic><topic>Digital technology</topic><topic>Economic impact</topic><topic>FDA approval</topic><topic>Health care</topic><topic>Health technology assessment</topic><topic>Humans</topic><topic>Intervention</topic><topic>Medical equipment</topic><topic>Medical personnel</topic><topic>Mobile Applications</topic><topic>Pandemics</topic><topic>Patients</topic><topic>Recruitment</topic><topic>Reimbursement</topic><topic>Research methodology</topic><topic>Review</topic><topic>Risk assessment</topic><topic>Selection bias</topic><topic>Sensitivity analysis</topic><topic>Software</topic><topic>Systematic review</topic><topic>Telemedicine</topic><topic>Uncertainty</topic><topic>Value</topic><topic>Virtual reality</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sapanel, Yoann</creatorcontrib><creatorcontrib>Tadeo, Xavier</creatorcontrib><creatorcontrib>Brenna, Connor T A</creatorcontrib><creatorcontrib>Remus, Alexandria</creatorcontrib><creatorcontrib>Koerber, Florian</creatorcontrib><creatorcontrib>Cloutier, L Martin</creatorcontrib><creatorcontrib>Tremblay, Gabriel</creatorcontrib><creatorcontrib>Blasiak, Agata</creatorcontrib><creatorcontrib>Hardesty, Chris L</creatorcontrib><creatorcontrib>Yoong, Joanne</creatorcontrib><creatorcontrib>Ho, Dean</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Applied Social Sciences Index & Abstracts (ASSIA)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Social Science Premium Collection</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Library & Information Science Collection</collection><collection>ProQuest Central</collection><collection>Library & Information Sciences Abstracts (LISA)</collection><collection>Library & Information Science Abstracts (LISA)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Library Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of medical Internet research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sapanel, Yoann</au><au>Tadeo, Xavier</au><au>Brenna, Connor T A</au><au>Remus, Alexandria</au><au>Koerber, Florian</au><au>Cloutier, L Martin</au><au>Tremblay, Gabriel</au><au>Blasiak, Agata</au><au>Hardesty, Chris L</au><au>Yoong, Joanne</au><au>Ho, Dean</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Economic Evaluation Associated With Clinical-Grade Mobile App-Based Digital Therapeutic Interventions: Systematic Review</atitle><jtitle>Journal of medical Internet research</jtitle><addtitle>J Med Internet Res</addtitle><date>2023-08-01</date><risdate>2023</risdate><volume>25</volume><issue>1</issue><spage>e47094</spage><epage>e47094</epage><pages>e47094-e47094</pages><issn>1438-8871</issn><issn>1439-4456</issn><eissn>1438-8871</eissn><abstract>Digital therapeutics (DTx), a class of software-based clinical interventions, are promising new technologies that can potentially prevent, manage, or treat a spectrum of medical disorders and diseases as well as deliver unprecedented portability for patients and scalability for health care providers. Their adoption and implementation were accelerated by the need for remote care during the COVID-19 pandemic, and awareness about their utility has rapidly grown among providers, payers, and regulators. Despite this, relatively little is known about the capacity of DTx to provide economic value in care.
This study aimed to systematically review and summarize the published evidence regarding the cost-effectiveness of clinical-grade mobile app-based DTx and explore the factors affecting such evaluations.
A systematic review of economic evaluations of clinical-grade mobile app-based DTx was conducted following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 2020 guidelines. Major electronic databases, including PubMed, Cochrane Library, and Web of Science, were searched for eligible studies published from inception to October 28, 2022. Two independent reviewers evaluated the eligibility of all the retrieved articles for inclusion in the review. Methodological quality and risk of bias were assessed for each included study.
A total of 18 studies were included in this review. Of the 18 studies, 7 (39%) were nonrandomized study-based economic evaluations, 6 (33%) were model-based evaluations, and 5 (28%) were randomized clinical trial-based evaluations. The DTx intervention subject to assessment was found to be cost-effective in 12 (67%) studies, cost saving in 5 (28%) studies, and cost-effective in 1 (6%) study in only 1 of the 3 countries where it was being deployed in the final study. Qualitative deficiencies in methodology and substantial potential for bias, including risks of performance bias and selection bias in participant recruitment, were identified in several included studies.
This systematic review supports the thesis that DTx interventions offer potential economic benefits. However, DTx economic analyses conducted to date exhibit important methodological shortcomings that must be addressed in future evaluations to reduce the uncertainty surrounding the widespread adoption of DTx interventions.
PROSPERO International Prospective Register of Systematic Reviews CRD42022358616; https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022358616.</abstract><cop>Canada</cop><pub>Gunther Eysenbach MD MPH, Associate Professor</pub><pmid>37526973</pmid><doi>10.2196/47094</doi><orcidid>https://orcid.org/0009-0009-3578-9594</orcidid><orcidid>https://orcid.org/0000-0003-0727-7611</orcidid><orcidid>https://orcid.org/0000-0002-0162-9885</orcidid><orcidid>https://orcid.org/0000-0001-6797-7850</orcidid><orcidid>https://orcid.org/0000-0002-6126-3897</orcidid><orcidid>https://orcid.org/0000-0001-9001-3128</orcidid><orcidid>https://orcid.org/0000-0001-5410-791X</orcidid><orcidid>https://orcid.org/0000-0001-9002-7933</orcidid><orcidid>https://orcid.org/0009-0007-0922-558X</orcidid><orcidid>https://orcid.org/0000-0002-7337-296X</orcidid><orcidid>https://orcid.org/0000-0003-0356-826X</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1438-8871 |
ispartof | Journal of medical Internet research, 2023-08, Vol.25 (1), p.e47094-e47094 |
issn | 1438-8871 1439-4456 1438-8871 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10427932 |
source | Applied Social Sciences Index & Abstracts (ASSIA); MEDLINE; DOAJ Directory of Open Access Journals; PubMed Central; EZB Electronic Journals Library; PubMed Central Open Access |
subjects | Bias Clinical assessment Clinical outcomes Clinical research Clinical trials Clinical Trials as Topic Cost analysis Cost control Cost-Benefit Analysis COVID-19 Digital technology Economic impact FDA approval Health care Health technology assessment Humans Intervention Medical equipment Medical personnel Mobile Applications Pandemics Patients Recruitment Reimbursement Research methodology Review Risk assessment Selection bias Sensitivity analysis Software Systematic review Telemedicine Uncertainty Value Virtual reality |
title | Economic Evaluation Associated With Clinical-Grade Mobile App-Based Digital Therapeutic Interventions: Systematic Review |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T20%3A29%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Economic%20Evaluation%20Associated%20With%20Clinical-Grade%20Mobile%20App-Based%20Digital%20Therapeutic%20Interventions:%20Systematic%20Review&rft.jtitle=Journal%20of%20medical%20Internet%20research&rft.au=Sapanel,%20Yoann&rft.date=2023-08-01&rft.volume=25&rft.issue=1&rft.spage=e47094&rft.epage=e47094&rft.pages=e47094-e47094&rft.issn=1438-8871&rft.eissn=1438-8871&rft_id=info:doi/10.2196/47094&rft_dat=%3Cproquest_pubme%3E2844677956%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2917629630&rft_id=info:pmid/37526973&rfr_iscdi=true |